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Edited by Sandro SonninoAbstract Rat hearts perfused for up to 60 min in the working
mode with palmitate, but not with glucose, resulted in substantial
formation of palmitoylcarnitine and stearoylcarnitine. To test
whether lipolysis of endogenous lipids was responsible for the
increased stearoylcarnitine content or whether some of the
perfused palmitate underwent chain elongation, hearts were
perfused with hexadecanoic-16,16,16-d3 acid (M+3). The penta-
ﬂuorophenacyl ester of deuterium labeled stearoylcarnitine had
an M+3 (639.4 m/z) compared to the unlabeled M+0 (636.3
m/z) consistent with a direct chain elongation of the perfused
palmitate. Furthermore, the near equal isotope enrichment of
palmitoyl- (90.2 ± 5.8%) and stearoylcarnitine (78.0 ± 7.1%)
suggest that both palmitoyl- and stearoyl-CoA have ready access
to mitochondrial carnitine palmitoyltransferase and that most of
the stearoylcarnitine is derived from the perfused palmitate.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The fatty acid demand of non-lipogenic tissues, such as skel-
etal muscle and heart, is met by uptake from the circulation. In
these tissues the major metabolic fate of fatty acids is their b-
oxidation primarily in the mitochondrial matrix for produc-
tion of ATP. However, fatty acids also are needed for the syn-
thesis of phospholipids which represent a major constituent of
membranes. The fatty acid composition of these phospholipids
often shows tissue as well as organelle speciﬁcity which
requires remodeling of the free fatty acid derived from the
circulation. While the reactions required for tissue speciﬁc
remodeling (chain elongation, desaturation) are relatively well
known for lipogenic tissues, little is known for non-lipogenic
tissues such as the heart and skeletal muscle. In studies with
isolated rat cardiac myocytes Hagve and Sprecher [1] could
ﬁnd no evidence for chain elongation of 14C-labeled 18:2,
18:3, 20:4, and 20:5 fatty acids. Likewise, no chain elongation
activity could be detected by Hamilton and Saggerson [2] in
any heart subcellular fraction either by measuring directly
the condensing enzyme with palmitoyl-CoA and malonyl-*Corresponding author. Fax: +1 216 3686644.
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of radioactivity from malonyl-CoA into lipid-soluble products
in the presence of palmitoyl-CoA. In contrast, Jimenez et al. [3]
reported the ability of cardiac myocytes to metabolize radio-
labeled linoleic acid to higher and more unsaturated metabo-
lites and that this activity signiﬁcantly decreased with age. In
the Langendorf perfused rabbit heart, Ford et al. [4] docu-
mented a signiﬁcant conversion of [9,10-3H] octadec-9 0-enoic
acid to [3H] eicosenoylcarnitine in ischemic, but not in control,
myocardium.
Recently, we observed that rat hearts perfused in the work-
ing mode with unlabeled palmitate plus glucose, but not with
glucose alone, also contain increasing amounts of stearoylcar-
nitine with time. This ﬁnding lead us to postulate that some of
the perfused palmitic acid was used to synthesize stearic acid.
In the present work we directly tested this hypothesis by per-
fusing isolated rat hearts with stable isotope labeled palmitic
acid (hexadecanoic-16,16,16-d3 acid) and analyzing the long-
chain acylcarnitines by HPLC/MS.2. Materials and methods
2.1. Chemicals
Unlabeled palmitic acid (P99.0% GC) was from Fluka and hexa-
decanoic-16,16,16-d3 acid (min 99 at.% D) from Isotech. All other
chemicals were of highest quality commercially available.
2.2. Heart perfusion
Six month Fisher 344 rats were obtained from a colony maintained
by the National Institute of Aging (Harlan Sprague Dawley, Inc., IN).
The animals, housed in our animal care facility in a temperature and
humidity controlled room and 12 h light/dark cycle, had free access
to food and water until the experiments. On the day of an experiments
the animals were weighed, injected with 500 U heparin (IP), killed with
Na-pentobarbital (100 mg/kg body weight) and the hearts canulated
for perfusion. The perfusion protocol consisted of a 15 min non-recir-
culating perfusion in the Langendorf mode with Krebs–Henseleit buf-
fer containing 5.5 mM glucose and 0.1 U/L insulin, followed by 15 and
60 min perfusion in the working mode (left atrial ﬂow 35–50 ml/min at
a preload of 10–15 mmHg) with 5.5 mM glucose/0.1 U/L insulin/3%
BSA alone (glucose perfused) or with 1.2 mM unlabeled palmitate
(M+0) or hexadecanoic-16,16,16-d3 acid (M+3) complexed to 3%
BSA in the presence of glucose/insulin (palmitate perfused) [5]. At
the end of perfusion the hearts were freeze-clamped, powdered under
liquid nitrogen and the powdered tissue stored at 60 C.
2.3. Fatty acid and acylcarnitine analysis
Unlabeled and stable isotope labeled palmitic acid was methylated
and the methylesters subjected to gas chromatography (inj. temp.:
240 C; temp. gradient 60–320 C) with mass spectrometric detectionblished by Elsevier B.V. All rights reserved.
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derivatized with pentaﬂuorophenacyl triﬂuoromethanesulfonate and
analyzed by HPLC/MS [7].3. Results and discussion
In rat hearts perfused with unlabeled palmitic acid plus
glucose, but not with glucose alone, there is an increase in
myocardial palmitoylcarnitine and myristoylcarnitine, as well
as of stearoylcarnitine (Table 1). While the increase in palmi-
toylcarnitine (and myristoylcarnitine) in palmitate perfused
hearts is expected, the increase in stearoylcarnitine is not
expected and raises questions about the source of stearate pres-
ent in stearoylcarnitine. Is it a contaminant present in commer-
cial palmitic acid, is it released from endogenous lipids during
perfusion with palmitate or is it derived from perfused palmi-
tate by chain elongation?
To address the purity of unlabeled palmitic acid used in per-
fusion experiments we ﬁrst analyzed the palmitic acid by gas
chromatography/mass spectrometry (GC/MS). Out of four
commercially available palmitic acid preparations only one
was >99% pure (Fluka) even though all were labeled and sold
as >99% pure. Since stearate was below the limit of detection
in the commercial palmitate obtained from Fluka and used in
the current perfusion experiments, stearate contamination can
not be the source for stearoylcarnitine formation (data not
shown). Although the lack of long-chain acylcarnitine accumu-
lation in hearts perfused with glucose alone made lipolysis as
the source of the stearoyl moiety unlikely, increased generation
of endogenous stearate due to increased lipid remodeling dur-
ing palmitate perfusion could not be ruled out. Thus, to deter-
mine if the stearoyl moiety of stearoylcarnitine is derived from
lipolysis of endogenous lipids or by chain elongation of
perfused palmitate, rat hearts were perfused with hexadeca-
noic-16,16,16-d3 acid (M+3) (by GC/MS free of stearate
contamination, data not shown) and the myocardial acylcarni-
tines analyzed. Fig. 1 shows the chromatographic separation
and mass spectrometric detection of acylcarnitine pentaﬂuor-
ophenacyl esters formed by the heart during a 60 min perfu-
sion with stable isotope labeled palmitate (hexadecanoic-
16,16,16-d3 acid) (Fig.1A). For comparison, a chromatogram
of long-chain acylcarnitine pentaﬂuorophenacyl esters ob-
tained by perfusing hearts with unlabeled palmitic acid under
otherwise identical conditions as in Fig.1A is presented in
Fig. 1B. The insets in Fig. 1A and B show the mass isotopomer
distribution of palmitoylcarnitine and stearoylcarnitine as well
as of myristoylcarnitine pentaﬂuorophenacyl esters. As shown
in inserts in Fig. 1A when hearts are perfused with hexadeca-
noic-16,16,16-d3 acid most of the palmitoylcarnitine formedTable 1
Palmitoyl-, stearoyl-, and myristoylcarnitine contents of rat hearts at baseline
unlabeled palmitic acid plus glucose and perfusion for 60 min with glucose o
Substrate/perfusion (min) Myristoylcarnitine (C14)
Baseline (no perfusion) 1.6 ± 0.6
Palmitate + glucose/15 min 15.0 ± 0.8
Palmitate + glucose/60 min 28.3 ± 5.9
Glucose only/60 min 3.7 ± 0.9
Values represent the means ± S.E.M. of four separate experiments and are eis of M+3 species (611.3 m/z) with 9.8 ± 5.8% (n = 4,
mean ± S.D.) representing M+0 species (608.3 m/z). Since the
perfused deuterated palmitic acid was greater than 99 at.%
deuterium, the presence of M+0 species indicates some dilution
of the perfused palmitic acid by unlabeled endogenous palmitic
acid. As with palmitoylcarnitine, most of the formed stearoyl-
carnitine was of M+3 species (639.4 m/z) with 22.0 ± 7.2%
(n = 4, mean ± S.D.) of unlabeled M+0 (636.3 m/z). Thus,
the formation of deuterated stearoylcarnitine (M+3) during
palmitate perfusion provides unequivocal evidence for fatty
acid chain elongation in the heart. In addition, the presence
of M+3 myristoylcarnitine indicates b-oxidation of labeled
palmitate (compare Fig. 1A vs 1B). The near identical enrich-
ment of stable isotope in palmitoyl- and stearoylcarnitine as
judged from the 611.3/608.3 and 639.4/636.3 m/z ratios, i.e.,
90.2 ± 5.8% and 78.0 ± 7.1%, respectively suggests that a frac-
tion of the perfused palmitic acid is directly chain elongated to
stearate at a site, probably mitochondria, where both, palmi-
toyl-CoA (substrate) and stearoyl-CoA (product) have direct
access to carnitine palmitoyltransferase. Consistent with our
interpretation are data published by Ford et al. [4] who per-
fused rabbit hearts with radiolabeled oleic acid and found that
the chain elongated product, eicosenoic acid, was conﬁned to
the carnitine fraction with no accumulation in other lipid clas-
ses, such as triglycerides, phospholipids, and fatty acids. Our
data clearly show that rat heart contains all the enzymes nec-
essary for fatty acid chain elongation and also explain the ﬁnd-
ing reported by Cinti et al. [8] that the content of stearic acid
relative to palmitic acid in the heart is nearly twice that found
in plasma.
In further support of fatty acid chain elongation in the heart
it has been shown recently that ELOVL6 is expressed in the
heart [9–12]. This enzyme catalyzes the malonyl-CoA depen-
dent chain elongation of myristic, lauric and palmitic acids
to stearic acid with a substrate preference for palmitic acid
[9–11]. In addition to ELOVL6, rat heart also expresses
ELOVL1 and ELOVL5 [12], with ELOVL1 having a substrate
preference for saturated and monounsaturated fatty acids and
ELOVL5 for polyunsaturated fatty acids [13].
In summary, using the fatty acid (hexadecanoic-16,16,16-d3
acid) perfused working rat heart model we provide experimen-
tal evidence for an active fatty acid chain elongation pathway
in the heart. While the data do not allow conclusion about the
subcellular localization of the pathway, the near identical iso-
tope enrichment in palmitoylcarnitine and stearoylcarnitine
suggests that at least some of the substrate palmitoyl-CoA
and product stearoyl-CoA of the chain elongation have ready
access to carnitine palmitoyltransferase and is indicative of a
mitochondrial fatty acid chain elongation pathway. Further
studies are required to elucidate the mechanism and substrate(no perfusion), after 15 and 60 min perfusion in the working mode with
nly
Palmitoylcarnitine (C16) Stearoylcarnitine (C18)
2.5 ± 1.0 1.3 ± 0.3
166.6 ± 31.7 12.7 ± 3.6
119.2 ± 39.0 32.9 ± 9.9
3.8 ± 1.2 2.8 ± 0.6
xpressed as nmol/g tissue wet weight.
Fig. 1. HPLC separation and mass spectrometric analysis of long-chain acylcarnitines extracted from rat hearts perfused for 60 min with 16,16,16-d3
palmitate (M+3) (A) and unlabeled palmitate (M+0) (B). Peak labeling: myristoylcarnitine (1); palmitoylcarnitine (2); heptadecanoylcarnitine –
internal standard (3); stearoylcarnitine (4). The insets in A and B show the mass isotopomer distribution of unlabeled (M+0) and deuterium labeled
(M+3) pentaﬂourophenacyl esters of myristoylcarnitine (580.2; 583.3), palmitoylcarnitine (608.3; 611.3), and stearoylcarnitine (636.3; 639.4),
respectively.
J. Kerner et al. / FEBS Letters 581 (2007) 4491–4494 4493speciﬁcity of the mitochondrial fatty acid chain elongation
pathway as well as its submitochondrial localization and met-
abolic signiﬁcance.
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